Immunic, Inc. (NASDAQ:IMUX) Given Average Recommendation of “Buy” by Brokerages

Shares of Immunic, Inc. (NASDAQ:IMUX) have been assigned an average recommendation of “Buy” from the eight ratings firms that are currently covering the company, MarketBeat reports. Six investment analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $12.67.

Several brokerages have recently commented on IMUX. D. Boral Capital restated a “buy” rating and set a $17.00 target price on shares of Immunic in a report on Tuesday, January 7th. StockNews.com upgraded Immunic from a “sell” rating to a “hold” rating in a report on Friday, January 31st. Finally, HC Wainwright assumed coverage on Immunic in a report on Monday, November 25th. They set a “buy” rating and a $10.00 target price on the stock.

Immunic Price Performance

Immunic stock opened at $0.98 on Thursday. The stock has a fifty day moving average price of $1.08 and a two-hundred day moving average price of $1.29. The firm has a market capitalization of $88.72 million, a P/E ratio of -0.80 and a beta of 1.87. Immunic has a 52-week low of $0.92 and a 52-week high of $2.11.

Immunic (NASDAQ:IMUX) last announced its earnings results on Thursday, November 7th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.02). During the same period in the prior year, the company posted ($0.51) earnings per share. On average, equities research analysts predict that Immunic will post -0.94 EPS for the current fiscal year.

Insider Activity at Immunic

In related news, Director Richard Alan Rudick bought 87,300 shares of the business’s stock in a transaction on Tuesday, November 12th. The shares were purchased at an average price of $1.15 per share, with a total value of $100,395.00. Following the completion of the purchase, the director now owns 87,300 shares of the company’s stock, valued at $100,395. This represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. 3.00% of the stock is owned by company insiders.

Hedge Funds Weigh In On Immunic

Hedge funds have recently added to or reduced their stakes in the stock. Virtu Financial LLC acquired a new position in Immunic in the third quarter valued at about $50,000. Jane Street Group LLC raised its position in shares of Immunic by 121.4% during the third quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock worth $116,000 after purchasing an additional 38,553 shares during the period. HB Wealth Management LLC acquired a new stake in shares of Immunic during the fourth quarter worth about $81,000. Connor Clark & Lunn Investment Management Ltd. raised its position in shares of Immunic by 70.8% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock worth $169,000 after purchasing an additional 42,383 shares during the period. Finally, State Street Corp raised its position in shares of Immunic by 7.5% during the third quarter. State Street Corp now owns 167,145 shares of the company’s stock worth $276,000 after purchasing an additional 11,642 shares during the period. Institutional investors and hedge funds own 51.82% of the company’s stock.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.